PT661992E - Formulacoes farmaceuticas de inibidores de interleucina-1 - Google Patents

Formulacoes farmaceuticas de inibidores de interleucina-1

Info

Publication number
PT661992E
PT661992E PT93921651T PT93921651T PT661992E PT 661992 E PT661992 E PT 661992E PT 93921651 T PT93921651 T PT 93921651T PT 93921651 T PT93921651 T PT 93921651T PT 661992 E PT661992 E PT 661992E
Authority
PT
Portugal
Prior art keywords
inhibitors
interleucin
interleukin
pharmaceutical formulations
pharmaceutical compositions
Prior art date
Application number
PT93921651T
Other languages
English (en)
Inventor
Benjamin K Sabados
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT661992E publication Critical patent/PT661992E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT93921651T 1992-09-17 1993-09-17 Formulacoes farmaceuticas de inibidores de interleucina-1 PT661992E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94700692A 1992-09-17 1992-09-17

Publications (1)

Publication Number Publication Date
PT661992E true PT661992E (pt) 2004-05-31

Family

ID=25485348

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93921651T PT661992E (pt) 1992-09-17 1993-09-17 Formulacoes farmaceuticas de inibidores de interleucina-1

Country Status (19)

Country Link
EP (1) EP0661992B1 (pt)
JP (1) JP3626755B2 (pt)
KR (1) KR950703358A (pt)
AT (1) ATE257389T1 (pt)
AU (1) AU675969B2 (pt)
CA (1) CA2141953C (pt)
CZ (1) CZ291261B6 (pt)
DE (1) DE69333378T2 (pt)
DK (1) DK0661992T3 (pt)
ES (1) ES2213744T3 (pt)
FI (1) FI951250A7 (pt)
HU (1) HU219445B (pt)
NO (1) NO321453B1 (pt)
NZ (1) NZ256328A (pt)
PL (1) PL175705B1 (pt)
PT (1) PT661992E (pt)
RO (1) RO113528B1 (pt)
RU (1) RU2126262C1 (pt)
WO (1) WO1994006457A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
DK0885002T3 (da) * 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
RU2153352C1 (ru) * 1999-08-09 2000-07-27 Гончар Александр Михайлович Фармацевтическая композиция, обладающая ранозаживляющим и противовоспалительным действием
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
JP4610154B2 (ja) * 2002-05-30 2011-01-12 大塚製薬株式会社 注射用製剤
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
PT1729810T (pt) * 2004-04-02 2018-11-22 Swedish Orphan Biovitrum Ab Publ Métodos de redução da agregação de il-ira
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
EP2217258B1 (en) 2007-11-14 2014-03-26 General Regeneratives Limited Use of interleukin-1 receptor antagonist as a myeloprotective agent
EP2244709A4 (en) * 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
AU2010317842A1 (en) 2009-11-16 2012-07-12 Mellitech [1,5]-diazocin derivatives
CN103221422B (zh) 2010-07-29 2017-03-29 十一生物治疗股份有限公司 嵌合il‑1受体i型激动剂和拮抗剂
WO2012078101A1 (en) * 2010-12-07 2012-06-14 Swedish Orphan Biovitrum Ab (Publ) Method for the treatment of il-1 mediated diseases
JP5937622B2 (ja) * 2011-02-11 2016-06-22 スウェディッシュ オーファン バイオビトラム パブリーク アクチエボラグ アナキンラを含み、クエン酸塩を含まない薬学的組成物
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
RU2014107743A (ru) * 2011-07-29 2015-09-10 Илэвэн Байотерапьютикс, Инк. Очищенные белки
SG10201707477SA (en) 2013-03-13 2017-10-30 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
MX2018005146A (es) * 2015-10-30 2018-08-23 Bonac Corp Composicion que contiene de manera estable molecula de acido nucleico de un solo filamento que suprime la expresion de gen tgf-b1.
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP4526469A1 (en) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
WO2026003765A1 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5416568B2 (pt) * 1972-09-29 1979-06-23
JPS537491B2 (pt) * 1972-09-30 1978-03-18
WO1992012724A1 (en) * 1991-01-17 1992-08-06 The Upjohn Company Method of preventing and treating insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
CZ64395A3 (en) 1995-10-18
ES2213744T3 (es) 2004-09-01
JP3626755B2 (ja) 2005-03-09
HU9500790D0 (en) 1995-05-29
PL308543A1 (en) 1995-08-21
RO113528B1 (ro) 1998-08-28
HUT71679A (en) 1996-01-29
DE69333378T2 (de) 2004-07-01
EP0661992B1 (en) 2004-01-07
NZ256328A (en) 1997-06-24
RU2126262C1 (ru) 1999-02-20
NO321453B1 (no) 2006-05-15
FI951250L (fi) 1995-03-16
AU4927693A (en) 1994-04-12
EP0661992A1 (en) 1995-07-12
CA2141953C (en) 2008-04-08
NO951006D0 (no) 1995-03-15
AU675969B2 (en) 1997-02-27
JPH08504755A (ja) 1996-05-21
CA2141953A1 (en) 1994-03-31
ATE257389T1 (de) 2004-01-15
PL175705B1 (pl) 1999-01-29
FI951250A0 (fi) 1995-03-16
DK0661992T3 (da) 2004-04-05
CZ291261B6 (cs) 2003-01-15
HU219445B (hu) 2001-04-28
FI951250A7 (fi) 1995-03-16
DE69333378D1 (de) 2004-02-12
WO1994006457A1 (en) 1994-03-31
KR950703358A (ko) 1995-09-20
NO951006L (no) 1995-03-15

Similar Documents

Publication Publication Date Title
PT661992E (pt) Formulacoes farmaceuticas de inibidores de interleucina-1
RU95106996A (ru) Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидные соединения, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
SE7903186L (sv) Cerebralverksamt medel
EA199800772A1 (ru) Производные 6-фенилпиридил-2-амина
ATE162725T1 (de) Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
DK0902789T3 (da) Androstenderivater
DE69432984D1 (de) Therapeutische substituierte guanidine
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
SE9201628D0 (sv) Pharmaceutical composition
EA199900876A1 (ru) Фармацевтические композиции против кашля
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
FI935777A0 (fi) Inhibitorer foer HIV-proteas anvaendbara vid behandling av AIDS
IT8423263A1 (it) Formulazioni farmaceutiche acquose di piroxicam monoidrato
IL139318A0 (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE69418035D1 (de) Hiv-proteaseinhibitoren
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
ES2091039T3 (es) Nuevos bis-fenil-hexenos.
PT1100463E (pt) Novas formulacoes injectaveis contendo ramoplanina
RU95106624A (ru) Гидроксиэтиламиносульфонамиды, промежуточные соединения, фармацевтическая композиция, способ ингибирования ретровирусных протеаз, способ лечения ретровирусных инфекций, способ лечения спида
KR960033467A (ko) 뮤신분비 억제제